Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636175 · ClinicalTrials.gov registry record · Early Phase 1
64Cu-LLP2A for Imaging Hematologic Malignancies
A Early Phase 1 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT06636175 is a Early Phase 1 study of Multiple Myeloma and Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 42 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06636175, a Early Phase 1 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Conditions Studied
Interventions
- DEVICE PET/CT
- DRUG 64Cu-LLP2A
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06636175
The ClinicalTrials.gov registry entry for NCT06636175 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which PET/CT is the first listed.
NCT06636175 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06636175 about?
NCT06636175 is a clinical study titled "64Cu-LLP2A for Imaging Hematologic Malignancies". This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expan...
What is the current status of trial NCT06636175?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2025-02-26. Estimated completion is 2027-03-31.
What conditions does trial NCT06636175 study?
This clinical trial studies the following conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma.
What interventions are being tested in trial NCT06636175?
The interventions under investigation include: PET/CT (DEVICE), 64Cu-LLP2A (DRUG).
Who is sponsoring clinical trial NCT06636175?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636175 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
RECRUITING · Early Phase 1
-
VitD3 Supplementation in Patients With Multiple Myeloma
RECRUITING · Early Phase 1
-
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
RECRUITING · Early Phase 1
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
RECRUITING · Early Phase 1
-
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.